Japanese Researcher And American Team Finds Human Umbilical Cord Blood Cells Altered Alzheimer’s Disease
This article was originally published in PharmAsia News
Japan's Saitama Medical Center researcher Takashi Mori and a University of South Florida team found that infusing human umbilical cord blood cells into mice altered Alzheimer's disease-like pathology. Alzheimer's disease is caused by irregular accumulation of beta-amyloid, resulting in nerve cell death. Currently, AD drug development worldwide aims to inhibit the accumulation of beta-amyloid. The research team found that after infusing low-dose human umbilical cord blood cells into 10 mice born with a tendency for easy beta-amyloid accumulation, within two to four weeks, beta-amyloid levels were reduced by around 70 percent compared to control. (Click here for more - Japanese language
You may also be interested in...
Drug companies involved in Alzheimer's disease research are a little fed up with FDA. Some, like Wyeth, believe the agency should put Alzheimer's research higher up on its priority list and allow the use of surrogate endpoints for clinical trials. But FDA says that no validated surrogate exists for Alzheimer's, and until it has hard data from products in development, it is loath to recommend one. A recent reorganization of the agency's neurology group may provide an opening to press home those arguments.
Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a ‘public benefit company’ could have far-reaching significance for the industry – if it ever gets off the ground.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.